Consensus Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-18 pm EDT			5-day change	1st Jan Change
11.44 ^USD	-1.80%		+0.70%	-3.30%

Jul. 10	Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04:20 PM
Jul. 10	AI Mania Masks Trade War Risks

Evolution of the Average Target: Roivant Sciences Ltd.

Evolution of the Target Price: Roivant Sciences Ltd.

Changes in Analyst Recommendations: Roivant Sciences Ltd.

893ca697d0424a13e16c8f51b.-O2hsTUEB9TmoOLrrKq9DQx_7MOEEYR7J6oFE6nTWjc.u6rq21xgarCOkq6ym_znRFkm3qXiS-8TUP8oJ-7mLlGdpJH3Z2tDoayNtw~39cc90a55f4b78fd727f55304269be6d

Analysts' recommendations: Roivant Sciences Ltd.

Piper Sandler Adjusts Price Target on Roivant Sciences to $22 From $20, Maintains Overweight Rating	24-07-10	MT
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	24-04-03	MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	24-04-03	MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	24-04-03	MT
Wolfe Research Initiates Roivant Sciences With Outperform Rating, $17 Price Target	24-02-15	MT
Deutsche Bank Initiates Coverage on Roivant Sciences With Buy Rating, $14 Price Target	23-12-12	MT
Goldman Sachs Raises Roivant Sciences Price Target to $16 From $14, Maintains Buy Rating	23-09-27	MT
HC Wainwright Adjusts Roivant Sciences Price Target to $18 From $15, Maintains Buy Rating	23-06-29	MT
Truist Securities Adjusts Price Target on Roivant Sciences to $23 From $19, Maintains Buy Rating	23-06-23	MT
BofA Securities Starts Roivant Sciences at Neutral With $10.50 Price Target	23-06-08	MT
JPMorgan Adjusts Roivant Sciences Price Target to $14 From $12, Maintains Overweight Rating	23-05-18	MT
HC Wainwright Adjusts Price Target on Roivant Sciences to $15 From $14, Maintains Buy Rating	23-05-17	MT
JPMorgan Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Overweight Rating	23-02-13	MT
Goldman Sachs Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	23-01-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $14 From $11, Maintains Buy Rating	23-01-05	MT
SVB Securities Adjusts Price Target on Roivant Sciences to $10 From $8, Maintains Outperform Rating	22-12-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	22-11-15	MT
Citigroup Raises Roivant Sciences' Price Target to $10 From $9, Maintains Buy Rating	22-08-16	MT
SVB Securities Adjusts Roivant Sciences' Price Target to $7 from $6, Keeps Outperform Rating	22-06-29	MT
Goldman Sachs Adjusts Roivant Sciences Price Target to $12 From $15, Maintains Buy Rating	22-05-24	MT
Goldman Sachs Lowers Roivant Sciences; Price Target to $12 From $15, Maintains Buy Rating	22-05-24	MT
SVB Securities Initiates Roivant Sciences at Outperform With $6 Price Target	22-05-23	MT
Cantor Fitzgerald Initiates Roivant Sciences at Overweight with $15 Price Target	22-04-29	MT
Goldman Sachs Starts Roivant Sciences at Buy With $15 Price Target	21-12-15	MT
HC Wainwright Initiates Roivant Sciences at Buy With $14 Price Target	21-11-08	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Ecart obj. / dr
ROIVANT SCIENCES LTD.		+48.6%
ELI LILLY AND COMPANY		+23.4%
JOHNSON & JOHNSON		+6.56%
ABBVIE INC.		+10.52%
NOVO NORDISK A/S		+55.34%
ROCHE HOLDING AG		+16.31%
NOVARTIS AG	-	+5.22%
ASTRAZENECA PLC		+33.22%
MERCK & CO., INC.		+27.3%
AMGEN INC.		+6.38%
Average		+23.28%
Weighted average by Cap.		+20.78%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.44USD

Average target price

17.00USD

Spread / Average Target

+48.60%

High Price Target

22.00USD

Spread / Highest target

+92.31%

Low Price Target

12.00USD

Spread / Lowest Target

+4.90%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Deutsche Bank Securities
Goldman Sachs
HC Wainwright
Wolfe Research
Truist Securities
BofA Securities
JPMorgan Chase
Citigroup
SVB Securities LLC
Cantor Fitzgerald
SVB Leerink
Jefferies & Co.
Cowen